Sanofi to sell stake in Covid-19 treatment maker Regeneron
Sanofi
€91.23
17:19 26/04/24
Sanofi will sell its stake in US-based maker of Covid-19 treatments Regeneron Pharmaceuticals.
AstraZeneca
11,988.00p
16:40 26/04/24
Bank of America Corp.
$37.83
11:09 26/04/24
CAC 40
8,088.24
17:00 26/04/24
DJ EURO STOXX 50
4,939.01
23:59 25/04/24
Dow Jones I.A.
38,239.66
04:30 15/10/20
FTSE 100
8,139.83
17:09 26/04/24
FTSE 350
4,470.09
16:59 26/04/24
FTSE All-Share
4,423.59
17:14 26/04/24
Goldman Sachs Group Inc.
$427.57
10:59 26/04/24
GSK
1,653.00p
16:40 26/04/24
Nasdaq 100
17,718.30
12:15 26/04/24
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
Regeneron Pharmaceuticals Inc.
$883.20
11:24 26/04/24
Regeneron is the manufacturer of the Kevzara treatment which was undergoing phase III trials for use against Covid-19 and was slated to start human trials for a so-called cocktail of treatments against the illness provoked by the novel coronavirus, know as REGN-Cov2, in June.
According to Bloomberg, the sale of the stake, worth approximately $13bn, would boost Sanofi's war chest to $50bn.
It could spark similar moves both by Sanofi itself and by some of the companies in which the French pharmaceutical giant had significant shareholdings.
Sanofi might repurchase Loreal's 9.4% stake in the pharma company and that Loreal might buy back Nestle's 23% stake in its own capital.
Regeneron announced on Monday that it would repurchase a $5bn stake from Sanofi with the French outfit planning to divest a holding worth roughly $7bn in parallel, for the largest public equity offering in the healthcare space, according to Bloomberg.
Sanofi boss, Paul Hudson, said the proceeds from the sale, equating to about 20.6% of Regeneron's share capital, would finance the firm's strategy of driving innovation and growth.
It also followed a near 57% leap in the stock over the preceding six months.
Bank of America and Goldman Sachs had been chosen to underwrite the sale, with the latter set to provide $1.5bn to finance the transaction and Regeneron paying for the rest in cash.
Already last December, Hudson had broached a possible sale of its stake in Regeneron, but at the time it was subject to a lock-up period expiring in December 2020.
The terms of the lock-up had since been amended.
Study results appeared to indicate that Kevzara may only be useful in helping the most severe Covid-19 patients.